89bio Gains Regulatory Consent for Pegozafermin's Phase 3 Program in NASH, Accelerating Treatment Access for Severe Liver Disease Patients
In a significant development for 89bio Inc, the biopharmaceutical company has successfully reached alignment with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the Phase 3 p...
Dec 4, 2023
Clinical Study
